Search
Dallas, TX Paid Clinical Trials
A listing of 1489 clinical trials in Dallas, TX actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1009 - 1020 of 1489
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 1489 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Randomized Multicenter Study for Isolated Skin Vasculitis
Recruiting
Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Dosing of Overground Robotic Gait Training with Functional Outcomes and Neuroplasticity After Spinal Cord Injury
Recruiting
The DOOR SCI project examines dosing effects of robotic gait training (RGT) and transcranial magnetic stimulation (TMS) initiated during inpatient rehabilitation and continued through early outpatient rehabilitation
Gender:
ALL
Ages:
Between 16 years and 85 years
Trial Updated:
02/04/2025
Locations: Baylor Scott & White Institute for Rehabilitation, Dallas, Texas
Conditions: Spinal Cord Injuries
Blood Purification for the Treatment of Pathogen Associated Shock
Recruiting
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following:
• Pathogen associated shock defined as:
* The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation
* Presence... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Septic Shock
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
Recruiting
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/04/2025
Locations: Site 103, Dallas, Texas
Conditions: Cataract
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Expanded Population Health Model Evaluation
Recruiting
This study will evaluate the impact of a comprehensive wellness and social determinants of health intervention on cardiovascular health in a community setting of the Bonton neighborhood. Participants will not be assigned to intervention activities, but health and wellbeing indicators will be collected in relation to how they choose to participate in activities over the year.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Baylor Scott & White Health and Wellness Center, Dallas, Texas
Conditions: Chronic Disease, Quality of Life
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Recruiting
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Study of PYX-201 in Solid Tumors
Recruiting
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: NEXT Dallas, Dallas, Texas
Conditions: Solid Tumor, Advanced Solid Tumor
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Texas Oncology, Dallas, Texas
Conditions: Myelofibrosis
Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry
Recruiting
A retrospective multicenter, observational design intended to capture data on pediatrics (weighing between 8 - 20 kg) who underwent continuous renal replacement therapy (CRRT) using the HF20 set. Data will be compared with a similar population (weighting 8-20 kg) from the ppCRRT registry who received CRRT with Prismaflex M60 sets.
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Children's Medical Center of Dallas, Dallas, Texas
Conditions: Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
SELUTION 4 De Novo Small Vessel IDE Trial
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.
The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Baylor Scott and White - Dallas, Dallas, Texas
Conditions: Coronary Artery Disease
1009 - 1020 of 1489